Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors

Inclusion Criteria

• •DISEASE CHARACTERISTICS: Histologically proven (except for brain stem tumors) malignancy that has
• •failed or relapsed after standard first-line antineoplastic therapy
• •Sarcoma (soft tissue and bone)
• •Kidney tumors
• •Brain tumors
• •Other solid tumors (gonadal and germ cell tumors, malignant melanoma,
• •retinoblastoma, liver tumors, and miscellaneous tumors) Must have had recurrence within the past 4 weeks
• •No bone marrow involvement
• •No prior or concurrent myelogenous leukemia
• •PATIENT CHARACTERISTICS:
• •Age:
• •1 to 21
• •Performance status:
• •Lansky or Karnofsky 60-100%
• •Life expectancy:
• •At least 12 weeks
• •Hematopoietic:
• •Absolute neutrophil count greater than 1000/mm3
• •Platelet count greater than 100,000/mm3
• •No grade III or IV thrombosis
• •Hepatic:
• •Bilirubin less than 1.5 times upper limit of normal (ULN)
• •SGOT or SGPT less than 2.5 times ULN
• •Renal:
• •Creatinine clearance or glomerular filtration rate at least 70 mL/min
• •Cardiovascular:
• •Ejection fraction normal
• •No evidence of arrhythmias requiring therapy
• •Fractional shortening greater than 28%
• •Other:
• •Not pregnant or nursing
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •At least 10 days since prior colony-stimulating factor therapy and recovered
• •At least 30 days since prior epoetin alfa
• •No other concurrent cytokines, including epoetin alfa
• •Chemotherapy:
• •At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and
• •recovered
• •At least 3 months since therapy with etoposide, carboplatin, or ifosfamide
• •that is identical to study treatment
• •Endocrine therapy:
• •Not specified
• •Radiotherapy:
• •Concurrent radiotherapy allowed after third course of therapy
• •No prior cranial/spinal radiotherapy
• •No prior radiotherapy to greater than 50% of bone marrow
• •Surgery:
• •Concurrent surgery allowed after the second course of therapy
• •Other:
• •No concurrent investigational agents
• •No concurrent lithium, aspirin, coumadin, or heparin